Logo

Proteome Sciences Licenses Stroke Biomarkers to Undisclosed Dx Firm

Jun 29, 2006

NEW YORK, June 29 (GenomeWeb News) - Proteome Sciences licensed its stroke biomarkers to "one of the top 10 global leaders in clinical diagnostics," the company said yesterday.

 

Under the research license, a number of Proteome Sciences biomarkers will be tested inclusion in a new panel for a high-throughput diagnostic platform. After incorporating the stroke markers, the licensee will develop an HTS stroke test, Proteome Sciences said in a statement.

 

The licensee declined to be identified by Proteome Sciences, citing competitive reasons. Proteome Sciences did say this is a new area for the licensee.

 

No financial details were disclosed.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.